Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com

Omeros (NASDAQ:OMER) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

Several other equities research analysts have also weighed in on OMER. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Tuesday. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Down 3.8 %

OMER stock traded down $0.31 during midday trading on Tuesday, reaching $7.91. The company had a trading volume of 1,877,015 shares, compared to its average volume of 545,573. The stock has a 50 day moving average price of $8.64 and a 200 day moving average price of $7.61. The firm has a market capitalization of $458.38 million, a PE ratio of -3.42 and a beta of 2.03. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of Omeros by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after purchasing an additional 6,839 shares during the period. State Street Corp grew its position in Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after buying an additional 3,839 shares in the last quarter. Nomura Holdings Inc. increased its stake in Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after buying an additional 430,932 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after buying an additional 18,454 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Omeros by 8.8% during the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after buying an additional 13,201 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.